Published in Can Fam Physician on November 01, 2014
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
Checklists for the use of novel oral anticoagulants by the front-line clinician. Can Pharm J (Ott) (2015) 0.91
Well-managed warfarin is superior to NOACs. Can Fam Physician (2015) 0.84
Safety of heparin bridging therapy for transrectal ultrasound-guided prostate biopsy in patients requiring temporary discontinuation of antithrombotic agents. Springerplus (2016) 0.75
Response. Can Fam Physician (2015) 0.75
Areas of improvement in anticoagulant safety. Data from the CACAO study, a cohort in general practice. PLoS One (2017) 0.75
Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med (2009) 39.97
Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med (2011) 28.99
Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med (2011) 23.50
Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med (2011) 7.30
Reversal of rivaroxaban and dabigatran by prothrombin complex concentrate: a randomized, placebo-controlled, crossover study in healthy subjects. Circulation (2011) 6.47
Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost (2010) 4.45
Periprocedural bleeding and thromboembolic events with dabigatran compared with warfarin: results from the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) randomized trial. Circulation (2012) 4.33
Assessment of laboratory assays to measure rivaroxaban--an oral, direct factor Xa inhibitor. Thromb Haemost (2010) 3.03
Focused 2012 update of the Canadian Cardiovascular Society atrial fibrillation guidelines: recommendations for stroke prevention and rate/rhythm control. Can J Cardiol (2012) 2.96
New oral anticoagulants in addition to single or dual antiplatelet therapy after an acute coronary syndrome: a systematic review and meta-analysis. Eur Heart J (2013) 2.81
Effect of non-specific reversal agents on anticoagulant activity of dabigatran and rivaroxaban: a randomised crossover ex vivo study in healthy volunteers. Thromb Haemost (2012) 2.61
Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost (2010) 2.47
Thrombolysis in an ischemic stroke patient on dabigatran anticoagulation: a case report. Cerebrovasc Dis (2012) 2.13
Apixaban, an oral, direct factor Xa inhibitor: single dose safety, pharmacokinetics, pharmacodynamics and food effect in healthy subjects. Br J Clin Pharmacol (2013) 1.69
Fatal intracerebral hemorrhage associated with administration of recombinant tissue plasminogen activator in a stroke patient on treatment with dabigatran. Cerebrovasc Dis (2011) 1.67
Using the HEMOCLOT direct thrombin inhibitor assay to determine plasma concentrations of dabigatran. Blood Coagul Fibrinolysis (2012) 1.63
Pharmacokinetic profile of the oral direct thrombin inhibitor dabigatran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol (2005) 1.58
Laboratory monitoring of new anticoagulants. Am J Hematol (2010) 1.49
Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost (2011) 1.47
Acute management of bleeding in patients on novel oral anticoagulants. Eur Heart J (2012) 1.27
Poor prognosis in warfarin-associated intracranial hemorrhage despite anticoagulation reversal. Stroke (2012) 1.25
Analysis of upper gastrointestinal adverse events among patients given dabigatran in the RE-LY trial. Clin Gastroenterol Hepatol (2012) 1.24
Periprocedural management and approach to bleeding in patients taking dabigatran. Circulation (2012) 1.14
Effect of food, an antacid, and the H2 antagonist ranitidine on the absorption of BAY 59-7939 (rivaroxaban), an oral, direct factor Xa inhibitor, in healthy subjects. J Clin Pharmacol (2006) 1.10
Pharmacologic properties of the new oral anticoagulants: a clinician-oriented review with a focus on perioperative management. Curr Pharm Des (2010) 1.07
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07
The effect of food on the absorption and pharmacokinetics of rivaroxaban. Int J Clin Pharmacol Ther (2013) 1.00
Intravenous thrombolysis with recombinant tissue plasminogen activator in a stroke patient treated with dabigatran. Cerebrovasc Dis (2010) 0.99
Thrombolysis treatment for acute ischaemic stroke in a patient on treatment with dabigatran. Thromb Haemost (2011) 0.98
Concomitant use of medication with antiplatelet effects in patients receiving either rivaroxaban or enoxaparin after total hip or knee arthroplasty. Thromb Res (2012) 0.98
Accurate determination of rivaroxaban levels requires different calibrator sets but not addition of antithrombin. Thromb Haemost (2012) 0.97
The acute management of haemorrhage, surgery and overdose in patients receiving dabigatran. Emerg Med J (2013) 0.95
Mechanical valve thrombosis with dabigatran. J Am Coll Cardiol (2012) 0.89
Effect of multiple doses of omeprazole on the pharmacokinetics, pharmacodynamics, and safety of a single dose of rivaroxaban. J Cardiovasc Pharmacol (2011) 0.79
Dabigatran etexilate and concomitant use of non-steroidal anti-inflammatory drugs or acetylsalicylic acid in patients undergoing total hip and total knee arthroplasty: no increased risk of bleeding. Thromb Haemost (2012) 0.77
Intravenous tissue plasminogen activator treatment for ischemic stroke in dabigatran-treated patients. Acta Neurochir (Wien) (2011) 0.77
Approach to the new oral anticoagulants in family practice: part 1: comparing the options. Can Fam Physician (2014) 1.07